Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. This includes melanoma, lung cancer...
47 KB (4,870 words) - 15:14, 3 August 2024
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed...
13 KB (761 words) - 04:27, 31 March 2024
(EU), for second line treatment of metastatic melanoma in November 2012. Nivolumab, in combination with ipilimumab is indicated for the treatment of intermediate...
47 KB (4,659 words) - 01:32, 18 May 2024
molecules, and the first clinical trial was launched in 2006, evaluating nivolumab. As of 2017, more than 500 clinical trials involving PD-1 and PD-L1 inhibitors...
31 KB (3,266 words) - 05:29, 20 May 2024
the combination of CIMAvax with the PD-1 inhibitor checkpoint inhibitor nivolumab was safe and well tolerated in 13 people with advanced non-small cell...
16 KB (1,556 words) - 23:09, 17 July 2024
Cancer immunotherapy (section Nivolumab)
Approved checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and pembrolizumab. Dendritic cell therapy provokes anti-tumor responses...
89 KB (10,338 words) - 14:21, 16 July 2024
designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma. Relatlimab is a Lymphocyte activation gene-3 (LAG-3)...
7 KB (312 words) - 06:00, 3 January 2024
the immune system. Atezolizumab is an anti PD-L1 monoclonal antibody. Nivolumab and Pembrolizumab are anti PD-1 monoclonal antibodies. Ipilimumab is a...
51 KB (5,338 words) - 00:03, 27 August 2024
the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot be removed or have...
96 KB (7,620 words) - 00:01, 16 August 2024
evaluated whether Nivolumab can be used for the treatment of a Hodgkin's lymphoma. The evidence is very uncertain about the effect of Nivolumab for patients...
67 KB (6,611 words) - 05:25, 15 August 2024
combination trial for non-small cell lung cancer, and a combination trial with nivolumab for renal cell carcinoma. Sitravatinib is being evaluated in ongoing trials...
4 KB (257 words) - 06:01, 5 July 2024
antibody nivolumab (under the brand name Opdivo and developed by Bristol-Myers Squibb) were published in 2010. It was approved in 2014. Nivolumab is approved...
21 KB (2,093 words) - 02:41, 1 September 2024
Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab...
49 KB (4,964 words) - 04:02, 9 August 2024
survival benefits.[citation needed] In August 2018, the FDA approved nivolumab to treat patients with metastatic small cell lung cancer (SCLC) who failed...
54 KB (5,529 words) - 09:35, 4 August 2024
that do not. Treatment with pembrolizumab, atezolizumab, or combination nivolumab plus ipilimumab are all superior to chemotherapy alone against tumors...
90 KB (9,784 words) - 14:55, 21 June 2024
system to fight cancer. Nivolumab is a fully human IgG4 antibody targeting programmed death receptor 1 (PD-1). In 2015, nivolumab was approved for the treatment...
59 KB (6,487 words) - 18:42, 27 December 2023
recently reviewed. The evidence is very uncertain about the effect of Nivolumab for patients with a Hodgkin's lymphoma e.g. on the overall survival. Increased...
87 KB (8,529 words) - 04:57, 2 September 2024
inhibitors (e.g. sunitinib), checkpoint inhibitors (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab) Contrast agent Gadolininum based contrast...
20 KB (2,303 words) - 18:34, 27 July 2024
CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy". Investigational New...
9 KB (535 words) - 00:04, 25 August 2024
(NCT05678673) is a phase 3, randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell...
5 KB (188 words) - 23:55, 23 January 2024
activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab Mouse Afelimomab...
38 KB (4,316 words) - 10:24, 26 August 2024
earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto...
5 KB (324 words) - 09:20, 18 July 2024
a combination therapy with both anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) in October 2015. The molecular factors and receptors necessary making...
39 KB (5,010 words) - 05:27, 17 August 2024
[citation needed] In October 2020, the FDA approved the combination of nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adults...
97 KB (10,705 words) - 03:19, 29 August 2024
(BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors". European Journal of Medical Research...
4 KB (261 words) - 04:25, 26 February 2024
include the biologic immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor...
15 KB (1,427 words) - 19:06, 3 September 2024
for treatment of metastatic melanoma. In 2014, the U.S. FDA approved nivolumab, a monoclonal antibody to PD-1, for treatment of advanced melanoma. Its...
6 KB (615 words) - 07:01, 2 December 2023
(BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors". European Journal of Medical Research...
16 KB (1,485 words) - 10:55, 28 August 2024
Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma". ClinicalTrials...
17 KB (1,775 words) - 13:19, 1 May 2024
include the biologic immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor...
4 KB (386 words) - 15:36, 21 May 2024